|Mr. Oded S. Lieberman Ph.D., MBA||N/A||N/A||59|
|Mr. Roy Golan CPA, LLM||N/A||N/A||44|
|Dr. Oron Yacoby-Zeevi Ph.D., DVM||N/A||N/A||56|
|Dr. Sheila Oren M.D., MBA||N/A||N/A||55|
|Dr. Sharon Cohen-Vered Ph.D.||275.85k||N/A||51|
NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing drug-device combinations for the treatment of central nervous system (CNS) disorders. The companys levodopa and carbidopa (LD/CD) product candidates, which have completed Phase IIa clinical trial, include ND0612L and ND0612H for the treatment of patients with moderate and advanced Parkinsons disease. It is also developing ND0701, a subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinsons disease and who do not respond well to LD/CD; and ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimers disease, and schizophrenia. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.
NeuroDerm Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.